CLINICAL AND PRECLINICAL EVALUATION OF EFFICACY AND TOXICITY OF CAR-T CELL (ALL/AML) TREATMENTS
- ATMP development
- ALL
- AML
- Cell therapy
- Immunotherapy
- CAR-T cells
- Preclinical research (TRL 4-5)
- Clinical research (TRL 6-8)
Preclinical and clinical evaluation of the efficacy and toxicity (pre-regulatory) of CAR-T cell therapy treatments.
Combining expertise from the preclinical to the clinical stage, to assess the potential of the therapeutic solution.
Description
Scope of research activities
Preclinical and clinical research for the development of new CAR-T cell therapies.
- Preclinical (in vivo) evaluation studies of CAR-T cells (new CARs, new targets, new CAR+ cells)
- Ancillary studies: identification of predictive markers of CAR-T cell efficacy/toxicity
- Clinical protocol: immunomonitoring of patients treated with CAR-T cells
Conduct of studies
- Assessment and definition of project requirements
- Study design and project implementation
- Analysis and communication of results
Research infrastructure
Experimental and analysis platforms:
- Spectral cytometry (Aurora, Cytec)
- Imaging (IVIS, Incucyte)
- Animal facilities (immunodeficient NGS mice
Specifications
The platform
Assessing the anti-tumor potential of CAR-T cell therapies for hematological malignancies.
The studies
Mouse model to assess CAR-T cell efficacy and toxicity:
- Immunodeficient NGS mice
- i.v., i.p. or orthotopic injection of human tumor lines expressing the CAR target
In vitro model for evaluating CAR-T cell efficacy:
- Cytotoxicity tests (bioluminescence, Incucyte)
- 3D spheroids
Immunomonitoring of patients treated with CAR-T cells:
- Multiparametric cytometry
- Cytokine assay
Examples of partnerships
To test in humans the relevance of observations made in preclinical models of CAR-T cells.
Partner: Institut Pasteur /Inserm 1223 (Dr. Philippe Bousso, Unité "Dynamiques des Réponses Immunes »)
Terms
OPALE entity
U976 - HIPI
Team leader
Contact
Dr. Sandrine PalcyBusiness Development Director